Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Cécile Daccord, Igor Letovanec, Patrick Yerly, Jonathan Bloch, Adam Ogna, Laurent P. Nicod, John-David Aubert. First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension in sickle cell disease Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease Year: 2007 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations Source: Eur Respir Rev 2014; 23: 350-355 Year: 2014 Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature Source: Eur Respir J 2014; 44: 1275-1288 Year: 2014 Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Updates in pulmonary hypertension and other pulmonary vascular diseases Source: Breathe, 15 (3) 241; 10.1183/20734735.0187-2019 Year: 2019 Pulmonary vascular distensibility in pulmonary hypertension due to left heart disease Source: International Congress 2018 – Pulmonary hypertension: right ventricle function, haemodynamics and exercise Year: 2018 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 The imPAHct of diagnosis delay in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Pulmonary hypertension in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 892-905 Year: 2003 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease Source: Eur Respir J 2013; 41: 217-223 Year: 2013